Keyphrases
16S Ribosomal RNA (16S rRNA)
5%
Academic Hospital
7%
Acid-fast Bacilli
16%
Active Tuberculosis
12%
Ag85B
7%
Anti-tuberculosis Drugs
8%
Antibacterial Activity
30%
Antibacterial Agents
5%
Antibiotics
7%
Antimicrobial Activity
6%
Aqueous Extract
6%
Bedaquiline
26%
C-reactive Protein
9%
Cell-free
6%
Chest X-ray
8%
Clinical Outcomes
9%
Cloning Expression
6%
Continuation Phase
6%
COVID-19
26%
Culture Method
9%
Culture Results
5%
Delamanid
13%
Drug-resistant Pulmonary Tuberculosis
6%
East Java Indonesia
8%
Escherichia Coli
11%
Extended-spectrum beta-lactamase-producing Escherichia Coli
6%
Fermentation
5%
Fine-needle Aspiration Biopsy
6%
General Hospital
7%
GeneXpert
7%
Healthcare Workers
6%
Healthy Controls
5%
Indonesia
78%
Indonesian
18%
Indonesian Patients
6%
Inflammatory Cytokines
6%
Inhibitory Activity
7%
Intensive Phase
10%
Jember
6%
Lactic Acid Bacteria
7%
Latent Tuberculosis Infection
7%
Lung Damage
8%
Lung Tissue Damage
6%
Lung Tuberculosis
6%
Medical Records
9%
Methicillin-resistant Staphylococcus Aureus
7%
Minimum Inhibitory Concentration
6%
Moxifloxacin
7%
Multidrug-resistant
9%
Multidrug-resistant Organisms
6%
Multidrug-resistant Tuberculosis (MDR-TB)
67%
Mycobacterium
8%
Mycobacterium Tuberculosis (M. tb)
59%
N-acetyltransferase 2 (NAT2)
8%
Passiflora Edulis Sims
13%
Peripheral Blood Mononuclear Cells
6%
Pneumonia
6%
Pneumonia Patients
6%
Polymerase Chain Reaction
5%
Population Pharmacokinetic Model
6%
Potential Biomarkers
6%
Pulmonary TB Patients
10%
Pulmonary Tuberculosis
53%
QT Prolongation
14%
QTc Interval
14%
Radiological Diagnosis
6%
Red Passion Fruit
9%
Referral Hospital
11%
Rifampicin
21%
Rifampicin Resistance
11%
Rifampicin-resistant Tuberculosis
18%
Risk Factors
19%
Saccharum Officinarum
6%
Short-term Treatment
6%
Shorter Regimen
11%
Smear Positive
5%
Sputum
17%
Sputum Samples
8%
Staphylococcus Aureus
6%
Streptomyces Sp.
6%
Streptomycin
5%
Surabaya
40%
TB Patients
19%
Tertiary Referral Hospital
12%
Treatment Outcome
8%
Treatment Regimen
5%
Tuberculosis
52%
Tuberculosis Diagnosis
12%
Tuberculosis Patients
100%
Tuberculosis Treatment
14%
Type 1 Diabetes Mellitus (T1DM)
11%
Xpert
7%
Xpert MTB
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acid Fast Bacterium
11%
Adenosine Deaminase
6%
Antibacterial Activity
21%
Antibiotics
6%
Antiinfective Agent
14%
Antimicrobial Agent
6%
Atypical Mycobacterium
5%
Bedaquiline
29%
C Reactive Protein
6%
Coconut
6%
Coronavirinae
13%
Cross-Sectional Study
10%
Cytokine
6%
Delamanid
13%
Diabetes Mellitus
6%
Diseases
32%
Drug Resistant Tuberculosis
42%
Escherichia coli
12%
Extended Spectrum Beta Lactamase
6%
Extrapulmonary Tuberculosis
6%
Flavonoid
7%
Hibiscus sabdariffa
6%
Infection
10%
Infectious Agent
10%
Isoniazid
5%
Latent Tuberculosis
7%
Lung Injury
8%
Lung Tuberculosis
45%
Microorganism
7%
Minimum Inhibitory Concentration
5%
Moxifloxacin
8%
Multi-Drug-Resistant Tuberculosis
21%
Mycobacteria
6%
Mycobacterium Tuberculosis
40%
Passiflora edulis
9%
Pharmacokinetics
11%
Pharmacotherapy
6%
Prevalence
6%
Retrospective Study
9%
Rifampicin
32%
Side Effect
13%
Staphylococcus Aureus
10%
Streptomyces
9%
Tissue Injury
6%
Tuberculosis
17%
Tuberculostatic Agent
6%
Tumor Necrosis Factor
6%
Medicine and Dentistry
Acid Fast Bacterium
10%
Adenosine Deaminase
6%
Bedaquiline
9%
C Reactive Protein
6%
COVID-19
26%
Cross Sectional Study
5%
Delamanid
6%
Diabetes Mellitus
7%
Diagnosis
9%
Diseases
14%
Drug Resistant Tuberculosis
20%
Extrapulmonary Tuberculosis
7%
Fine-Needle Aspiration
5%
Infection
7%
Lung
5%
Lung Tuberculosis
31%
Medical Record
5%
Mixed Infection
7%
Multidrug Resistant Tuberculosis
12%
Mycobacterium Tuberculosis
23%
Patient Referral
8%
Retrospective Study
5%
Rifampicin
13%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Sputum
22%
Sputum Culture
6%
Systematic Review
6%
Tuberculosis
7%
Tuberculostatic Agent
8%